Business
Adagio Medical Announces Participation in the 19th Annual International Symposium on Ventricular Arrhythmias
LAGUNA HILLS, Calif.--(BUSINESS WIRE)-- Adagio Medical Holdings, Inc. (Nasdaq: ADGM; the “Company”), a leading innovator in catheter ablation technologies
About this update from Adagio Medical Holdings, Inc
[{"type":"text","content":" LAGUNA HILLS, Calif.--(BUSINESS WIRE)--\nAdagio Medical Holdings, Inc. (Nasdaq: ADGM; the “Company”), a leading innovator in catheter ablation technologies for treatment of cardiac arrhythmias, today announced its sponsorship and participation in the 19th Annual International Symposium on Ventricular Arrhythmias, to be held at the New York Marriott at the Brooklyn Bridge on October 11-12, 2024.\n\nIn addition to participating in the commercial exhibition, Adagio’s proprietary Ultra-Low Temperature Cryoablation (ULTC) technology will be featured within the scientific program of the Symposium.\n\nPresentation Details:\n\nDate: October 11, 2024\nTime: 4:40 p.m. ET\nTopic: Cryocure-VT: One-year Results and Next Steps (FULCRUM-VT)\nPresenter: Dr. Atul Verma, Director, Division of Cardiology at McGill University Health Centre and FULCRUM-VT Co-Principal Investigator\n\nDate: October 12, 2024\nTime: 12:35 p.m. ET\nTopic: PVC Ablation using Ultra-low Cryoablation (Recorded Case)\nPresenter: Professor Dr. Roland Tilz, Director of the Department of Rhythmology at the University Clinic Schleswig-Holstein\n\n“The annual VT Symposium is a seminal scientific and educational event for everyone involved and interested in the treatment of ventricular arrhythmias,” said Olav Bergheim, President and CEO of Adagio. “We are proud to be a continuing supporter and look forward to discussing our technology and clinical program with the top experts in the field.”\n\nAbout Adagio Medical\n\nAdagio Medical is an early commercial stage medical device company located in Laguna Hills, California focusing on developing innovative cryoablation technologies that create contiguous, transmural lesions to treat cardiac arrhythmias, including paroxysmal and persistent atrial fibrillation, atrial flutter, and ventricular tachycardia.\nView source version on businesswire.com: https://www.businesswire.com/news/home/20241007783534/en/\n\nMedia Contact\nIlya Grigorov\nVice President, Global Marketing and Product Management of Adagio Medical, Inc.\[email protected]\n\nInvestor Contact\[email protected]\n\nSource: Adagio Medical Holdings, Inc.","length":3556,"tagName":"div"}]